logo-loader
viewMedlab Clinical Ltd

Medlab Clinical expands nutraceutical business with FeverMates agreement

The company is developing therapies for pain management, depression and obesity as well as earning revenue from the sale of nutritional products in Australia and the US.

Medlab Clinical Ltd - Medlab Clinical expands nutraceutical business with FeverMates agreement
The agreement will licence several of Medlab’s existing nutraceuticals

Medlab Clinical Ltd (ASX:MDC) has executed a Heads of Agreement (HoA) with Randall Communications Pty Ltd, trading as FeverMates, to expand Medlab’s nutraceutical business in new foreign and domestic territories.

FeverMates is best known for the global distribution of fever management and prevention products including stick-on thermometers, hand sanitisers and medical face masks.

WATCH: Medlab Clinical's Dr Sean Hall details new FeverMates agreement

MDC chief executive officer Dr Sean Hall said: “The Randall Communications deal opens up international trade for MDC beyond our internal scope.

“FeverMates is a great established brand and we are honoured to work with them.”

Trading as FeverMates will expand MDC’s nutraceutical business to take advantage of new foreign and domestic opportunities and will licence several of Medlab’s existing nutraceuticals.

Expanding commercial offerings

Randall Communications, the owers of FeverMates, see value in expanding their commercial offerings to include several of the existing MDC nutraceuticals to the global market, inclusive of India and Eastern Europe.

Randall Communications managing director Michael Randall said: “FeverMates, a fast-growing global brand, is delighted to work with MDC to assist Australians in need by bringing high-quality, easily accessible and well-priced products to a larger market.”

Definitive agreement pending

The HoA allows both companies to negotiate the financial and commercial terms to be included in a definitive commercial agreement specifying products, territories and market channels.

MDC shares have been as much as 36% higher to an intra-day high of 32 cents, up from 13.5 cents on March 25.

Quick facts: Medlab Clinical Ltd

Price: 0.2 AUD

ASX:MDC
Market: ASX
Market Cap: $46.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medlab Clinical's Dr Sean Hall details new FeverMates agreement

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall caught up with Proactive's Andrew Scott after signing a Heads of Agreement (HoA) with Randall Communications Pty Ltd - trading as FeverMates. The deal will help to expand Medlab’s nutraceutical business in new foreign and domestic...

on 6/4/20

2 min read